Compare FTRE & BHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FTRE | BHC |
|---|---|---|
| Founded | 1996 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.3B |
| IPO Year | 2023 | 1996 |
| Metric | FTRE | BHC |
|---|---|---|
| Price | $21.06 | $8.21 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 13 | 7 |
| Target Price | ★ $22.63 | $7.70 |
| AVG Volume (30 Days) | 1.9M | ★ 3.0M |
| Earning Date | 10-29-2026 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 423.08 |
| EPS | ★ N/A | N/A |
| Revenue | $2,723,400,000.00 | ★ $8,724,000,000.00 |
| Revenue This Year | N/A | $6.81 |
| Revenue Next Year | $3.11 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.00 | N/A |
| 52 Week Low | $8.55 | $4.33 |
| 52 Week High | $26.16 | $9.04 |
| Indicator | FTRE | BHC |
|---|---|---|
| Relative Strength Index (RSI) | 45.85 | 74.93 |
| Support Level | $16.34 | $5.49 |
| Resistance Level | $21.25 | N/A |
| Average True Range (ATR) | 1.36 | 0.37 |
| MACD | -0.11 | 0.24 |
| Stochastic Oscillator | 15.57 | 78.69 |
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum of its revenue from the Bausch + Lomb segment.